Cognition Therapeutics 3Q 2026: EPS ($0.04) — 10-Q Summary
Cognition Therapeutics reported a narrower net loss of $4.15M in Q3 2026, with EPS at ($0.04), compared to ($0.06) a year ago. The company had no revenue but saw higher grant income and lower administrative expenses. Clinical development is progressing, with FDA feedback aligning on a key study and Phase 2 trial enrollment completed. Cash reserves totaled $31.5M, expected to last into Q4 2027.
How this was made
The 30-second read
Why it matters
The earnings release provides the first public view of the company's cash runway and loss improvement, offering a basis for short‑term trading decisions.
Market read
First‑time earnings disclosure for CGTX with improved loss metrics; relevant for biotech microcap traders.
What to watch
Upcoming Phase 2 data for the Alzheimer’s program could dominate future price moves.
Background
Cognition Therapeutics filed its Q3 2026 Form 10‑Q, reporting no revenue, higher R&D spend, and cash sufficient through Q4 2027.
Ticker impact
Q3 2026 net loss narrowed to $4.15M and diluted EPS improved to -$0.04, cash balance $31.5M.
potential modest upside as investors price in improved loss profile and liquidity.
The narrowed loss and stronger cash position reduce near‑term financing risk, likely supporting the stock.
Market effects
Biotech sector may see slight sentiment lift from a microcap improving its loss profile.
U.S. small‑cap biotech investors could adjust exposure.
Limited; impact confined to niche biotech investors.
Counterpoint
Loss narrowing may be modest and not enough to offset broader market weakness in biotech.
Key entities
- companyCognition Therapeutics Inc.
U.S. listed biotech focused on neurodegenerative disease therapies.
